engleski

Osteoprotegerin and bone markers in metabolic bone disorders

Bone turnover was assessed in patients with different metabolic bone diseases by standard bone markers and osteoprotegerin. This study comprised 43 women with postmenopausal osteoporosis, 36 kidney transplant recipients with stable graft function and 79 patients on chronic dialysis treatment. Bone alkaline phosphatase (BALP), telopeptide (CTX, crosslaps) and osteoprotegerin were measured in sera by commercial kits. Bone alkaline phosphatase was increased in 62% of osteoporotic, 72% of kidney transplant and 17% hemodialysis patients. Telopeptide was increased in 2% of osteoporotic, 50% of kidney transplant and 72% of hemodialysis patients. Positive and statistically significant correlation (p<0.01) existed for telopeptide with BALP, and also telopeptide with osteoprotegerin in the entire patient group. In the osteoporotic group no relationship existed between measured parameters. Statistically significant (p<0.0005) and positive correlation between telopeptide and BALP was observed in kidney transplant recipients and hemodialysis patients, and a negative correlation (p<0.04) between telopeptide and osteoprotegerin only in hemodialysis patients. The three groups differed (p<0.0005) regarding all measured parameters, the highest BALP in the kidney transplant, the highest telopeptide and osteoprotegerin in the hemodialysis group. Assessment for osteoprotegerin cut-off values was performed by ROC curve construction (area 0.675, p<0.0005) with positive cases of BALP and telopeptide greater than postmenopausal women reference data. The obtained results indicated that severity of bone disorder was reflected by increased telopeptide and also by correlations of BALP, telopeptide and osteoprotegerin. Measurement of osteoprotegerin may contribute to bone metabolism assessment together with BALP and telopeptide, and might be included in routine clinical laboratory tests.

bone; osteoporosis; osteoprotegerin; metabolic bone disease

nije evidentirano